NCT03162627: Selumetinib and Olaparib in Solid Tumors

NCT03162627
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known or suspected brain metastases or spinal cord compression, unless the condition has been asymptomatic
https://ClinicalTrials.gov/show/NCT03162627

Comments are closed.

Up ↑